Compare PXLW & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | VNRX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 31.9M |
| IPO Year | 2000 | 2012 |
| Metric | PXLW | VNRX |
|---|---|---|
| Price | $6.06 | $0.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.33 | $2.50 |
| AVG Volume (30 Days) | 25.7K | ★ 1.5M |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | $693,000.00 | ★ $1,233,511.00 |
| Revenue This Year | $5,066.23 | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.46 | $0.17 |
| 52 Week High | $15.42 | $0.94 |
| Indicator | PXLW | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 36.71 |
| Support Level | $5.67 | $0.17 |
| Resistance Level | $6.77 | $0.27 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 39.13 | 5.36 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.